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Abstract 
Simple, novel, rapid and cost effective UV-spectrophotometric method has been developed and 
validated for estimation of CYMT in bulk and tablet formulation. CYMT is a Phenothiazine derivative from the 
class of typical antipsychotic and a new drug for the treatment of Schizophrenia. As no analytical method was 
seen in literature for determination of CYMT; we report here, development and validation of simple, novel UV-
spectrophotometric method for analysis of CYMT. Drug was found to be soluble in water and was stable for 
more than 72 h in same solvent when tested for bench top stability; being ideal solvent, spectrophotometric 
studies were carried out using distilled water and detection as well as quantitation was performed at wavelength 
maximum of 267.21 nm. Linearity curve for developed method was generated by measuring absorbance at 
specified wavelength maximum and plotting it against concentration. The method followed linearity in range of 
2 - 12 µg/mL with a correlation coefficient of 0.999. The mean recovery of 98.97 reflects accuracy for 
developed method and the method precision was found to be well within acceptable limits. The developed 
method was tested and validated for various parameters as per USP requirements and recent ICH guidelines 
(addendum 2005). The present UV-spectrophotometric estimation for CYMT was proved to be statistically 
accurate, precise, and sensitive. The applicability of method can be extended towards rapid routine 
determination of drug in bulk and pharmaceutical formulations and it has the unique importance of being first 
and simple UV-Spectrophotometric analytical method for the determination of CYMT in bulk and in 
pharmaceutical formulation      
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1.Introduction 
Cyamemazine Tartrate (CYMT) (Fig. 1) is 
10-(3-dimethylamino-2-methyl-propyl)-
Phenothiazine-2-carbonitrile (Cyamemazine)1 and its 
tartrate (CYMT) belonging to class of typical 
antipsychotics and a new drug for the treatment of 
Schizophrenia2. CYM being a Phenothiazine 
derivative was introduced initially in clinical practice 
as an antipsychotic agent due to its Dopamine D2 
receptor antagonistic activity, however ample clinical 
experience indicated that drug was also usefull for 
the treatment of anxiety; Cyamemazine is a 
neuroleptic compound which possesses anxiolytic 
properties in humans3, 4. A previous binding study has 
shown that cyamemazine possesses high affinity for 
5-HT3- and 5-HT2C-receptor types5. The scifinder 
search was performed for the literature survey of 
Cyamemazine (CYM) as well as CYMT. Literature 
survey of CYM revealed very few methods for the 
analysis; viz…an LC-MS/MS tandem methodology 
was developed specifically for the identification of 
CYM and its metabolites during characterization of 
human cytochrome P450 enzymes involved in the 
metabolism of CYM6.  Bioanalytical methods were 
found with application GC-MS tandem mass 
spectrometry; as simultaneous determination for 
seven antipsychotic drugs7
 
and
 
quantification in 11 
biological fluids and tissues assisted with automated 
solid phase extraxtion8, while there was not a single 
method published in literature for the analysis of 
CYMT in bulk as well as in pharmaceutical 
formulations. Even there is scarcity of simple and 
stability indicating HPLC, HPTLC and UV-
spectrophotometric methods for the routine 
determination of CYM and hence for CYMT too. 
Considering the need of analytical 
investigations pertaining to the CYM and CYMT, 
simple methods such as estimation by UV-
Spectrophotometry will assist towards rapid 
determination of drug in bulk and pharmaceutical 
formulation. The objective of the present 
investigation was to establish simple, Zero order UV-
spectrophotometric method for estimation of CYMT.  
The developed method was applied effectively for 
determination of drug in bulk and in-house tablet 
formulation. Method was validated for accuracy, 
precision, sensitivity and ruggedness as per ICH 
guidelines9.   
Fig. 1: Structure of Cyamemazine Tartrate 
 
 
2. Experimental 
2.1 Materials and Equipments 
Cyamemazine Tartrate was supplied as 
generous gift sample. Water used for 
spectrophotometry was distilled water and used 
throughout the experimental work described. As the 
marketed formulation was unavailable in India, the 
in-house tablets have been prepared for the analysis 
of drug from pharmaceutical formulation and to 
justify the applicability sensitivity of the method for 
future analysis. The excipients used for preparation 
of in-house tablets were microcrystalline cellulose 
(MCC), and magnesium stearate: were purchased 
from Sigma Aldrich, Mumbai. 
Spectrophotometric studies were performed using 
UV-visible spectrophotometer (2450, Shimadzu), UV 
Probe 2.21, a pair of 10 mm matched quartz cells and 
spectral bandwidth 1 nm were employed for all 
samples. Solvents were investigated to develop UV- 
spectrophotometric method for the estimation of 
CYMT in in-house tablet formulations. Criteria taken 
into consideration while selecting solvent for present 
spectrophotometric analysis were solubility of 
Cyamemazine Tartrate in solvent systems, stability in 
different solvents or solvent compositions, steps 
involved in sample preparation, sensitivity, 
simplicity, cost effective analysis and applicability of 
method towards rapid estimation of drug in bulk and 
pharmaceutical formulations. Absorbance of CYMT 
in the selected solvent at wavelength maximum was 
determined. All the criteria listed above are fulfilled 
by water being universal solvent. As the drug was 
found to be soluble in water, method development 
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and validation of present UV-spectrophotometric 
method was assisted with distilled water as solvent.   
2.2 Physical Properties and Characteristics ad 
uses of Cyamemazine tartrate 
-Yellowish Colour 
-Soluble in Water and Methanol 
-Melting Point- 180-1840C 
-Bioavailability- 10-70% 
-Metabolism-Hepatic 
-Half-Life- 10 hrs. 
-Excreted in urine. 
-Routes - Oral, IM, IV. 
-Molecular formula: C23H27N3O6S 
-Used in Schizophrenia and especially for psychosis, 
anxiety, anxiolytic efficacy. 
2.3 Preparation of standard solution and study of 
linearity curves    
        Standard solution was prepared by dissolving 10 
mg of CYMT in 100 mL of distilled water to obtain 
concentration of 100 µg/mL. It was further diluted 
with the same solvent to obtain concentration of 10 
µg/mL and scanned in the UV-region of 400 − 200 
nm. Drug showed maximum absorption at a λmax of 
267.21 nm Fig 2. From the standard solution, aliquots 
in the range of 0.2 to 1.2 mL were transferred into a 
series of six 10 mL volumetric flasks and volume was 
made up to the mark to obtain concentration in the 
range of 2 - 12 µg/ mL. The absorbance obtained was 
plotted against the concentration to generate linearity 
curve for the method as depicted in Fig 3. The results 
for the linearity study of CYMT are as represented in 
Table 1. 
 
Table 1: Results of linearity studies for estimation of Cyamemazine Tartrate 
Sr. No Concentration of Cyamemazine Tartrate     (µg/ml) 
Absorbance Mean ± SD 
(n = 6) % RSD 
1 2 0.142  ±  0.0008 1.47 
2 4 0.245  ±  0.0008 1.71 
3 6 0.393  ±  0.0012 1.42 
4 8 0.519  ±  0.0014 1.21 
5 10 0.642  ±  0.0023 1.74 
6 12 0.765  ±  0.0022 1.19 
 
Fig. 2: UV-Spectrum for Estimation of Cyamemazine Tartrate depicting λmax at 267.21 nm 
 
 
Fig. 3: Calibration Curve for UV-Spectrophotometric estimation of 
Cyamemazine Tartrate 
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2.4 Preparation of in-house tablet formulation 
In-house tablets, containing 25 mg of 
CYMT per tablet, were prepared using simple direct 
compression technique. The excipients used were 
microcrystalline cellulose (MCC), and magnesium 
stearate. 
2.5 Validation of methods 
  The developed UV-spectrophotometric 
method was validated for Precision, Accuracy, 
Repeatability, Ruggedness, Sensitivity and the 
validated method was thus applied for the 
determination of CYMT in bulk and in in-house 
tablet formulation. 
2.6 Precision 
  Precision of the method was studied as intra-
day and inter-day variations. Intra-day precision was 
determined by analyzing the 6, 8 and 10 µg/mL of 
Cyamemazine Tartrate solutions for three times in the 
same day. Inter-day precision was determined by 
analyzing the 6, 8 and 10 µg/mL of Cyamemazine 
Tartrate solutions daily for three days, results are 
reported in Table 2. 
Table 2: Results from precision studies for estimation of Cyamemazine Tartrate 
Drug          Cyamemazine Tartrate  
Concentration 
[µg mL-1] 
Amount Found [µg mL-1] 
[n= 9] ± SD 
RSD 
[%] 
Intra-day Precision 
6 5.89 ± 0.0064 1.65 
8 8.06 ± 0.0060 1.13 
10 9.84 ± 0.0061 1.74 
Inter-day Precision 
6 5.79 ± 0.0062 1.58 
8 8.03 ± 0.0076 1.18 
10 9.74 ± 0.0060 0.67 
2.7 Recovery experiments  
  Accuracy of the methods was studied at 
three different levels i.e. 80, 100 and 120 % levels. 
To the pre-analyzed sample solution (6 µg/mL of 
CYMT) a known amount of standard drug was added 
and it was then reanalyzed by the proposed methods. 
The results for the recovery studies are as depicted in 
Table 3. 
Table 3: Results from Recovery Studies for estimation of Cyamemazine Tartrate 
Pre-analysed 
sample solution  
[µg/mL] 
Excess  
drug added  
[µg/mL] (%) 
Amount 
recovered 
[µg/mL] 
% Recovery 
(n = 3)  
% RSD 
 
       4 
3.2 (80) 3.92 99.21 1.54 
4.0 (100) 3.89 99.47 1.67 
4.8 (120) 3.84 98.25 1.72 
2.8 Repeatability 
  Repeatability was determined by analyzing 
6 µg/mL concentration of Cyamemazine Tartrate 
solution for six times.  
2.9 Ruggedness 
  Ruggedness of the proposed method was 
determined by analysis of aliquots from homogenous 
solution by two analysts using same operational and 
environmental conditions and the results are reported 
in Table 6. Proposed method was evaluated for 
ruggedness by analyzing fixed concentration of 6 
µg/mL of sample solution; by two different analysts 
keeping operational and environmental conditions 
identical and the results are reported in terms of % 
RSD. 
2.10 Sensitivity  
  The sensitivity of the method was 
determined as Limit of Detection (LOD) and Limit of 
Quantification (LOQ). To determine the limits of 
detection and quantification, concentrations at the 
lower end of the linear range of the calibration plot 
were analyzed. The LOD and LOQ were calculated 
with application of equations; LOD = 3.3 × N/B and 
LOQ = 10 × N/B; where, ‘N’ is the standard 
deviation of the peak areas of the drugs (n = 3), taken 
as a measure of noise, and ‘B’ is the slope of the 
corresponding calibration plot.  
2.11 Application of Developed UV-
spectrophotometric Method for Estimation of 
Cyamemazine Tartrate in Bulk and in in-house 
tablet formulation  
2.11.1 Determination of CYMT in Bulk: 
Accurately weighed 10 mg of CYMT was transferred 
to 100 ml volumetric flasks containing about 25 mL 
of distilled water, sonicated for 5 min and volume 
was made upto the mark using same solvent to obtain 
desired concentration 100 µg/ml. Aliquots of 6 
µg/mL were prepared and scanned on 
spectrophotometer in the UV range and absorbance 
was measured at 267.21 nm. The concentrations of 
the drug were calculated from linear regression 
equations; results are shown in Table 4. 
Table 4: Analysis of Cyamemazine Tartrate in Bulk 
Concentration 
[µg/mL] 
Amount Found 
(mg) 
Amount found 
(%) 
         6 
5.93 98.83333 
5.88 98.00001 
5.89 98.16667 
6.01 100.1667 
6.09 101.5 
5.96 99.33333 
Mean ± SD 5.96 ± 0.0079 99.3333 ± 1.3249 
% R.S.D. 1.33 1.33 
2.11.2 Assay of in-house tablet formulation 
  Twenty in-house tablets were selected 
randomly, weighed accurately and ground into fine 
power. An amount of powdered drug equivalent to 10 
mg was accurately weighed and transferred into a 
100 mL volumetric flask containing 25 mL of  
Distilled water, sonicated for 15 min and volume was 
made up to the mark followed by filtration through 
Whatmann filter paper number 41.  From this 
solution; appropriate volumes of 0.6 mL were diluted 
to 10 mL using distilled water. The resulting 
solutions were scanned by using UV-
spectrophotometer in the range of 400 - 200 nm. The 
same spectrum was recorded and absorbance 
obtained was measured. The amount of drug was 
estimated by using established linearity curve for the 
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method; results for the formulation assay are as represented in Table 5.  
Table 5: Analysis of Cyamemazine Tartrate in Tablet formulation 
Concentration                  
    [µg/mL] 
Amount Found  
(mg) 
Amount found  
(%) 
 
 
       6 
5.88 98.0 
5.91 98.05 
6.10 101.66 
6.11 101.83 
5.89 98.16 
6.03 100.5 
Mean ± SD 5.98 ± 0.010 99.777 ± 1.772 
% R.S.D. 1.771 1.776 
 
3. Results and Discussion  
  CYMT showed absorbance maximum at 
267.21 nm distilled water and followed linearity in 
the concentration range of 2 - 12 µg/mL. The 
developed zero order UV-spectrophotometric method 
was found to have the linear regression equation as y 
= 0.063 x + 0.0078 with regression coefficient (r2) of 
about 0.999. The intra-day and inter-day precision 
values (% RSD) were calculated and proved to be in 
acceptable limit (≤ 2%) for CYMT. Accuracy of was 
evaluated by percent recovery studies; performed at 
concentration levels of 80, 100 and 120 % and found 
to be within acceptable limits (≤ 2%) with mean 
percent recovery of 98.97 %. The percent amount of 
CYMT in in-house tablets as estimated by present 
UV-spectrophotometric method was found to be 
99.77 %. The results are as shown in Table-2.The 
results represented that there was no interference 
from the excipients that generally occurs in tablet 
formulation. The summary of validation parameters 
for the UV-spectrophotometric estimation areas 
depicted in Table 6. 
Table 6: Summary of validation parameters for UV-Spectrophotometric determination of Cyamemazine 
Tartrate 
Parameter UV-Spectrophotometry 
% Recovery (n= 9) 98.97 
% RSD 1.64 
Sensitivity   
LOD (µg/mL) 0.2 
LOQ (µg/mL) 0.6 
Precision [% RSD] 
Intra-day (n=3) 
 
1.13 - 1.74 
Inter-day (n=3) 0.67 - 1.58 
Repeatability [%RSD] (n=6) 1.50 
Ruggedness [± SD] 
Analyst – I (n= 6) 
 
98.05 ± 0.0067 
Analyst – II (n= 6) 99.14 ± 0.031 
 
4. Conclusion 
 The developed zero order UV-
spectrophotometric method was found to be rapid, 
economical and simple for determination of CYMT. 
Accuracy and precision are found within acceptable 
range (ICH Guideline Q2 (R1), 2005). Thus 
developed method can be used for routine analysis of 
CYMT in bulk and in its tablet formulation 
effectively. 
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